61 results about "Urea derivatives" patented technology

The invention relates to the technical field of medicines, in particular to fused tricyclic substituted isoxazolidinyl urea derivatives, pharmaceutically acceptable salts, stereoisomers, pharmaceutical compositions and application thereof. The structure of the fused tricyclic substituted isoxazolidinyl urea derivative is as shown in a formula (I). The fused tricyclic substituted isoxazolidinyl urea derivative disclosed by the invention has obvious TrkA kinase and cell inhibition activity and selective inhibition activity.

The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, 25% to 40% by weight of urea and / or urea derivatives relative to the total weight of the composition; at least one saccharide-free non-emulsifying hydrophilic gelling polymer; at least one scleroglucan gum; the composition containing less than 2% by weight of surfactant relative to the total weight of the composition, preferably less than 1%, even more preferably less than 0.5% or no surfactant at all. It also relates to the use of a cosmetic composition of this kind for skin care, in particular for the skin of the face or body, as well as to a cosmetic skin care method, in particular for the skin of the face or body, involving the application of a cosmetic composition of this kind.

Bisorthohydroxy aromatic urones and their use as curatives and cure accelerators in resin systems particularly epoxy resin systems provide formulations with good outlife, low curing temperatures and desirable glass transition temperatures after curing, they are particularly useful in prepregs used in the production of components for the aerospace and wind turbine industries.

A process for preparing a cyclic urea derivative by reacting an alkylene carbonate and a primary amine in the presence of a metal oxide catalyst to form the cyclic urea derivative.

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

This invention relates to a sprayable hair care product in the form of an oil-in-water emulsion, having a pH value of 3.0 to 7.0 at 20°C, comprising at least one water-insoluble oil component (A), at least one nonionic emulsifier (B), at least one nonionic co-emulsifier (C), water, and a buffer system for stabilizing the pH value, wherein the water content is equal to 60 to 90% by weight, component (A) is provided in an amount of 1.5 to 20% by weight, and components (B) and (C) are provided in a total amount of 1 to 12% by weight. The invention is characterized in that adenosine is provided in an amount of 0.01 to 3% by weight, and urea and / or urea derivatives are provided in a total amount of 1.0 to 25% by weight. This invention also relates to a method for preparing a sprayable aqueous formulation of adenosine, wherein an aqueous solution of adenosine is mixed with a finely dispersed emulsion of an oil component (A) such that the formulation contains 1.5 to 20% by weight of the emulsified oil component (A), wherein the average droplet diameter of the oil component (A) (measured using a device based on the principle of quasi-elastic light scattering (Zetasizer Nano ZS, 25°C, square polystyrene cuvette, 12 mm side length (model DTS0012), dilution: 0.025% w / w in water)) is less than 1 μm. During or after preparation and before mixing with the adenosine solution, the emulsion is brought to a phase transition temperature, and urea and / or urea derivatives are added to the resulting mixture at room temperature. This invention also relates to the use of a sprayable aqueous formulation containing adenosine and urea and / or urea derivatives with an ethanol content of less than 18% by weight for cosmetic treatment of the skin, particularly the scalp.

The present invention pertains to a process for preparing an isocyanate-containing compound comprising the step of reacting a compound of formula (1) (1) with oxalyl chloride.

The purpose of the present invention is to provide a method for simultaneously performing concentration and deproteinization of natural rubber latex.　The present invention relates to: a method for concentrating natural rubber latex, the method being characterized by adding a surfactant, urea or a urea derivative, a compound that is selected from the group consisting of hydroxide salts, ammonia and salts thereof, and optionally a polar organic solvent to natural rubber latex, introducing a gas containing at least 0.1-100% by volume of carbon dioxide into the natural rubber latex, leaving the natural rubber latex to stand still so as to separate the natural rubber latex into a cream phase and a serum phase, and recovering the cream phase; and a method for producing a concentrated natural rubber.

Bis-orthohydroxy aromatic urones and their use as curing agents and cure accelerators in resin systems, particularly epoxy resin systems, provide formulations with good longevity, low cure temperatures, and desirable glass transition temperatures after cure, and are particularly useful in prepregs used in the manufacture of parts for the aerospace and wind turbine industries.

The present invention relates to novel compounds for treating, alleviating or preventing diseases, disorders and abnormalities that respond to modulation of NLRP3 inflammasome pathway components or inhibition of their activation. In particular, the inflammasome pathway component is the NOD-like receptor (NLR) family pyrin domain-containing protein 3 (NLRP3) inflammasome. More particularly, the compounds of the present invention have the ability to modulate the NLRP3 inflammasome pathway. In addition, the compounds of the present invention are suitable for treating, alleviating or preventing diseases, disorders and abnormalities that respond to modulation, particularly reduction, of IL-1β and / or IL-18 levels. #imgabs0#

To provide an antimicrobial composition which has water solubility and exhibits superior antibacterial effects against Gram-positive bacteria.SOLUTION: An antimicrobial composition of the present disclosure contains a diiodomethane compound (A), a cyclodextrin derivative (B), and a compound (C), wherein the compound (C) includes at least one selected from the group consisting of pyrrolidones, organic acids, terpenes, urea and urea derivatives, alcohols, esters, chelating compounds, antioxidants, surfactants, and thioglycolic acid or salts thereof.SELECTED DRAWING: None

Described herein are novel piperidine urea derivative compounds and pharmaceutical compositions thereof for the treatment of neurodegenerative disorders and diseases mediated by soluble epoxide hydrolases.

A method for producing a carbamic acid salt, including contacting a carbon dioxide-containing mixed gas having a partial pressure of carbon dioxide of 0.001 atm or more and less than 1 atm with an amino group-containing organic compound in the presence of a base in at least one organic solvent selected from the group consisting of an organic solvent having 2 or more and 8 or less carbon atoms, and a method for producing a carbamic acid ester or a urea derivative using the carbamic acid salt.

The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, 25% to 40% by weight of urea and / or urea derivatives relative to the total weight of the composition; at least one saccharide-free non-emulsifying hydrophilic gelling polymer; at least one scleroglucan gum; the composition containing less than 2% by weight of surfactant relative to the total weight of the composition, preferably less than 1%, even more preferably less than 0.5% or no surfactant at all. It also relates to the use of a cosmetic composition of this kind for skin care, in particular for the skin of the face or body, as well as to a cosmetic skin care method, in particular for the skin of the face or body, involving the application of a cosmetic composition of this kind.

To provide an antimicrobial composition which exhibits superior antibacterial effects against at least one of Gram-positive bacteria and Gram-negative bacteria.SOLUTION: An antimicrobial composition of the present disclosure contains a diiodomethane compound (A) and a compound (B), wherein the compound (B) includes at least one selected from the group consisting of organic acids, terpenes, urea and urea derivatives, alcohols, esters, antioxidants, and surfactants.SELECTED DRAWING: None

To suppress polyene formation in a polarizer made of a polyvinyl alcohol resin film.SOLUTION: A polarizing plate 100 includes a polarizer 101 in which a dichroic dye is adsorbed and aligned on a polyvinyl alcohol-based resin film, and a protective film 103 laminated on at least one surface of the polarizer 101 via an adhesive layer 102. The adhesive layer 102 contains a urea compound. The polarizer 101 contains a radical scavenger. The urea compound is at least one selected from the group consisting of urea, urea derivatives, thiourea, and thiourea derivatives. The radical scavenger is a hindered amine compound.SELECTED DRAWING: Figure 1

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

Described herein are novel piperidine urea derived compounds and pharmaceutical compositions thereof for the treatment of conditions and diseases mediated by soluble epoxide hydrolases.

The present invention relates to the field of biological medicines. Disclosed are N-tetrazolyl aryl urea derivatives, a preparation method therefor, and the use thereof. The present invention has recently discovered the N-tetrazolyl aryl urea derivatives, and further found that the compounds have an antagonistic activity against bradykinin B1 receptor, so that the compounds can be used as novel bradykinin B1 receptor antagonists and can be further used for treating or preventing related diseases caused by abnormal expression of the bradykinin B1 receptor. In particular, the present invention has recently found that N-tetrazolyl aryl urea derivatives have prevention or treatment effects on corona virus disease 2019, pulmonary edema, diabetes complications, allergic conjunctivitis, etc.

A thermally expandable composition includes at least one epoxy-functional polymer, at least one endothermic chemical blowing agent, and at least one curative selected from the group made of a urea, urea derivatives, guanidine derivatives, amidine derivatives, and imidazoles. Further, a baffle and / or a reinforcement element for hollow structures includes the thermally expandable composition, a process manufactures the baffle and / or the reinforcement element, the baffle and / or the reinforcement element is used for sealing, baffling, or reinforcing of a cavity or a hollow structure, and a method seals, baffles and / or reinforces a cavity or hollow structure.

Described herein are novel piperidine urea derivative compounds and pharmaceutical compositions thereof for the treatment of cancer as monotherapy or in combination with chemotherapeutic agents and / or checkpoint inhibitors.

To provide a method for treating a disease mediated by cannabinoid 1 receptor (CB1R).SOLUTION: Heteroaryl and aliphatic analogs of diarylurea-based CB1R allosteric modulators of Formula (I) are provided. Exemplary analogs can provide improved potency and pharmacokinetic properties. Also provided are methods of using the analogs to treat diseases mediated by CB1R, such as substance abuse and adiposity.SELECTED DRAWING: None

A peptide-urea derivative, a pharmaceutical composition containing same and an application thereof are provided, the derivative being as shown in formula I. The derivative can be used for preoperative imaging diagnosis and grading of PSMA-positive prostate cancer, and can also be used for the treatment of various types and stages of prostate cancer, achieving the integration of diagnosis and treatment, and having broad application prospects.

The present invention relates to obtaining novel derivatives of amphoteric macrolides (such as amphotericin B) by modifying an insoluble amine in their structures (for example the amine group of the mycosamine of AmB) so as to introduce a urea function linked to a hydroxylated alkyl chain, making it possible to improve the solubility thereof, maintain or improve the activity thereof, and substantially reduce the toxicity thereof. In one embodiment, the derivatives are obtained by grafting carbohydrate urea derivatives. The invention also relates to the use of said carbohydrate urea derivatives as a function for solubilising amphoteric antibiotics and as a solubilisation adjuvant.

The present invention relates to a reducing agent, comprising: a sulfinate of formula I, wherein R1 is H or C1-C6 hydrocarbyl, R2 is C1-C6 hydrocarbyl or M', and M and M' are each independently at least one monovalent cation or a combination with at least one multivalent cation; and optionally, urea or a urea derivative. The reducing agent contains essentially no sulfonic acid or sulfonate. In addition, the present invention relates to a preparation method for the reducing agent. The reducing agent can effectively improve the properties of a polymerization product when used for emulsion polymerization and preparation of a water-soluble polymer.

The present invention is comprised in the field of medicinal chemistry, and it is related to substituted vinyl piperazine-piperidine urea compound which are well effective as antitumoral agents. In particular, they are suitable in methods of treatment of glioblastoma (GB), multiple myeloma (MM) or pancreatic cancer (PC).

The invention discloses an alkyne aromatic heterocyclic urea derivative, and particularly relates to a free alkali, an isomer or a pharmaceutically acceptable salt of the derivative and other substance forms. Furthermore, the invention also discloses a preparation method and pharmaceutical application of the alkyne aromatic heterocyclic urea derivative, and the alkyne aromatic heterocyclic urea derivative can be used as an RIPK1 inhibitor for treating diseases related to abnormal expression of a mediated RIPK1 signal channel, including but not limited to tumors, inflammatory diseases or diseases accompanied by inflammatory reactions, autoimmune diseases, neurodegenerative diseases and the like, and has a broad application prospect. The clinical development value is great.

The invention belongs to the technical field of chemical medicines, and provides a ferroptosis-inducing urea derivative as well as a preparation method and anti-tumor application thereof. The ferroptosis-inducing urea derivatives are oxyurea, thiourea and squaramide sorafenib derivatives, the anti-proliferative activity on HT1080 human fibrosarcoma cells is remarkably enhanced by modifying the structure of a sorafenib mother nucleus, and in-vitro experiments show that the inhibition effect of the ferroptosis-inducing urea derivatives is more than one time higher than that of sorafenib. The series of derivatives play an anti-tumor role by activating a ferroptosis pathway, and can potentially overcome the drug resistance problem of sorafenib. The invention further provides a synthetic route, a purification method and an in-vitro pharmacodynamic evaluation system of the derivative, and a structure optimization strategy and candidate compounds are provided for developing novel antitumor drugs of a targeted ferroptosis pathway.

The invention discloses a preparation method and application of a pyridylpiperazine modified quinazolinyl-aryl urea derivative, and the method comprises the following steps: taking 4-chloro-6, 7-dimethoxy quinazoline as a raw material, reacting with 3-nitrobenzylamine hydrochloride to obtain an intermediate 2, adopting a demethylation reagent to remove methyl at the 6-position of a quinazoline ring with high selectivity to obtain the pyridylpiperazine modified quinazolinyl-aryl urea derivative. The preparation method comprises the following steps: firstly, preparing a key intermediate 3, modifying a hydrophilic group pyridyl piperazine unit and a lipophilic group (alkyl with four carbon atoms) on the basis of the intermediate, then reducing, and finally reacting with phenyl isocyanate (or phenyl isocyanate derivative) to obtain a target product. The method is simple, efficient and high in yield, a plurality of compounds in the product obtained by adopting the method show good proliferation inhibition effects on tumor cells of human bladder cancer, osteosarcoma, pancreatic cancer, breast cancer, cervical cancer and the like, and the product is good in water solubility and fat solubility and has the potential to become a tumor molecular targeting drug.